HUMDF (Hua Medicine) Valuation Rank


HUMDF Hua Medicine HUMDF
46 GF Score
Price $0.34
GF Value $1.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Hua Medicine Valuation Rank Related Terms

HUMDF
46GF Score
Hua Medicine HUMDF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hua Medicine (HUMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HUMDF:

  • Valuation Rank:
  • GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hua Medicine Business Description

Other Exchanges 02552:Hong Kong
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score

Get the complete analysis for HUMDF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$1.46
GF Value